New Danish biotech company offers drug firms clinical trials service  

PhaseOne Trials is the first independent Danish biotech company to offer drug firms Phase 1/2 clinical trials

Newly established Danish biotech company PhaseOneTrials will be the first independent Danish company to offer Phase 1 & 2 clinical trials of drugs to pharmaceutical and biotech companies. Clinical phase 1 trials include voluntary healthy individuals, while phase 2 includes smaller groups of patients. Former research director of the Clinical Research Unit at Hvidovre Hospital, Dr. Kim Krogsgaard, is the founder and a shareholder in the new company.


PhaseOneTrials has DKK 10 million (USD 1.5 million) in capital and reserves; investors include Hvidovre Hospital, HACS ApS, Industriudvikling A/S, Pensionskassen for Farmakonomer, OTK Holding A/S and Øresund Holding APS. It is expected that PhaseOneTrials will be ready to test new drugs from January 2004. The news is reported by

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×